What we do Indo Borax & Chemicals Ltd manufactures and sells boron and lithium chemical products, including boric acid and lithium hydroxide, catering to industrial and pharmaceutical sectors. |
Founded in 1,980 |
Market share A well-established player with a modern plant and significant capacity, catering primarily to Indian industrial and pharmaceutical markets. |
Problem solved Provides high-quality boron and lithium chemicals essential for metallurgical, pharmaceutical, and construction applications, addressing industrial demand for these chemicals. |
Top clients or who we serve Serves industrial manufacturers and pharmaceutical companies; operates mainly B2B. |
Key management Sajal Jain (Managing Director & CFO) has significant leadership role with a focus on financial and operational management. |
Our journey and innovations Founded in 1980; modernized facilities at Pithampur; FDA approved pharmaceutical-grade boric acid; added Di-Sodium Octaborate Tetrahydrate production in 2025. |
Where we operate Primarily India with sales focused domestic market; well connected logistic base in Madhya Pradesh. |
Top products or what we offer Boric Acid Technical & IP Grade, Di-Sodium Octaborate Tetrahydrate, Boron Oxide, Lithium Hydroxide Monohydrate. |
Top brands Not specifically branded products; known for quality boric acid and lithium chemical products with FDA pharmaceutical approval. |
Raw materials needed Borate minerals and lithium derivatives for processing into chemical products. |
Raw materials supplier Not specified in detail; procurement aligned with industry standards for boron and lithium sources. |
Recurring vs cyclical contribution Revenue largely recurring from ongoing industrial chemical demand, with some cyclicality reflecting overall industrial activity. |
Our industry position Leading Indian manufacturer with significant capacity and FDA pharmaceutical grade approval in boron chemicals segment. |
Financial highlights FY 2024-25 revenue Rs.175.26 Cr; net profit Rs.42.51 Cr; EBITDA and PAT improved by over 9% YoY despite slight revenue dip. |
Geographical revenue split Revenue predominantly from Indian markets; no specific export data provided. |
Order book - |
Whats driving growth Innovation in product range, added new products like DOT, steady industrial demand, operational efficiency, and regulatory approvals. |
Our future plans Focus on capacity utilization, product mix enhancement, and sustaining growth in core chemical segments. |
Our green promise Committed to environmental compliance, energy conservation, and safety in operations. |
Our people and values About 106 employees; emphasis on ethical governance, safety, inclusion, and low employee turnover. |
Key challenges ahead Managing raw material supply risks, competitive pressures, and regulatory compliance costs. |
Interesting facts Over 1600% oversubscription at 1993 IPO; FDA approval for pharmaceutical boric acid; added DOT production in 2025. |
Risks and strategy Mitigates supply and market risks via compliance, quality standards, diversified product mix, and robust internal controls. |
